9-β-D-arabinofuranosylguanine

We are 9-β-D-arabinofuranosylguanine CAS:38819-10-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:9-β-D-arabinofuranosylguanine
CAS.NO:38819-10-2
Synonyms:9-beta-D-arabinofuranosylguanine
Arabinosylguanine
Ara-G
9-arabinofuranosylguanine
9-b-D-Arabinofuranosylguanine
Molecular Formula:C10H13N5O5
Molecular Weight:283.24100
 
Physical and Chemical Properties:
Density:2.25
Boiling point:775.9ºC
Flash point:423.1ºC
Index of Refraction:1.955
 
Specification:
Appearance:White or off-white crystalline powder
Assay(HPLC):≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:For the manufacture of ATP (adenosine triphosphate), adenosine, coenzyme A, etc..

9-β-D-arabinofuranosylguanine


Related News: Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact.201856-53-3 Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact.1443-80-7 By drawing these distinctions between APIs and the drugs themselves, manufacturers are able to specialize and pharmacists able to align generic equivalents with brand names.5-hydroxymethyl Tolterodine Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).

Related Products
Product Name
METHYLTRI-N-PROPOXYSILANE View Details
3-BAEPF View Details
9,9-dimethyl-N-(2-phenylphenyl)fluoren-2-amine View Details
4-bromoanisole manufacturer 12-bromododec-1-ene manufacturer 2-Bromo-6-chlorobenzaldehyde manufacturer Fmoc-L-alaninol manufacturer 1-Bromo-4-(difluoromethoxy)benzene manufacturer